STOCK TITAN
  1. Home
  2. Sec-filings
  3. ETON
  4. [8-K] Eton Pharmaceuticals, Inc. Reports Material Event

Lower rates and extended interest-only period for Eton (NASDAQ: ETON) loan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Eton Pharmaceuticals entered into a sixth amendment to its credit agreement with SWK Funding LLC. The amendment lowers the loan’s interest rate from Secured Overnight Financing Rate (SOFR) plus 6.75% to SOFR plus 6.55% and reduces the SOFR floor from 5.0% to 2.75%.

The interest-only period was extended to November 2026, and Eton may choose to begin principal payments in May 2026 or defer them until November 2026. No fees were paid to SWK in connection with this amendment, and the loan’s maturity date remains in December 2027.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
New interest margin SOFR + 6.55% Amended SWK Credit Agreement
Prior interest margin SOFR + 6.75% Before sixth amendment
New SOFR floor 2.75% Amended loan terms
Prior SOFR floor 5.0% Original SWK Credit Agreement terms
Interest-only extension To November 2026 Interest-only period for SWK loan
Loan maturity December 2027 Maturity of amended SWK Credit Agreement
Secured Overnight Financing Rate financial
"the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75%"
A secured overnight financing rate (SOFR) is a daily benchmark interest rate that reflects the cost of borrowing cash overnight using U.S. Treasury securities as collateral. Think of it as the market price to “rent” cash for a day with a very safe pledge, similar to paying a short-term rental fee for money backed by government bonds. Investors track SOFR because it underpins pricing for loans, bonds and derivatives, so movements change borrowing costs, interest income and the valuation of interest-rate–linked positions.
SOFR floor financial
"with the SOFR floor reduced to 2.75% from the previous 5.0%"
interest only period financial
"Further, the interest only period was extended to November 2026"
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement"
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Understanding 8-K Material Events →
false 0001710340 0001710340 2026-04-09 2026-04-09
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
April 9, 2026
Date of Report (Date of earliest event reported)
 
 
ETON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-38738
37-1858472
(State of
(Commission
(I.R.S. Employer
incorporation)
File Number)
Identification Number)
 
21925 W. Field Parkway, Suite 235
Deer Park, Illinois 60010-7208
(Address of principal executive offices) (Zip code)
 
(847) 787-7361
(Registrant’s telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading symbol(s)
  
Name of each exchange on which registered
Common Stock, par value $0.001 per share
  
ETON
  
NASDAQ Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 1.01 Entry into a Material Definitive Agreement
 
On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%. Further, the interest only period was extended to November 2026, with the Company having the option to make principal payments in May 2026 or deferring principal payment to November 2026. There were no fees paid to SWK associated with the credit amendment and the amended credit agreement maturity date remained in December 2027.
 
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
 
Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 2.03 by reference.
 
Item 9.01 Financial Statements and Exhibits 
 
(d) Exhibits
 
Exhibit No.
  
Description
     
Exhibit 10.1   Sixth Amendment to Credit Agreement, dated April 9, 2026, by and among Eton Pharmaceuticals, Inc. and SWK Funding LLC.
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
3
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: April 15, 2026
By:
/s/ James R. Gruber
   
James R. Gruber
   
Chief Financial Officer and Secretary
   
(Principal Financial Officer)
 
4

Source: View Original Filing on SEC EDGAR

FAQ

What credit agreement change did Eton Pharmaceuticals (ETON) announce?

Eton Pharmaceuticals amended its credit agreement with SWK Funding LLC. The change lowers the interest rate spread and SOFR floor, extends the interest-only period, and keeps the existing December 2027 maturity, improving loan terms without paying additional fees to the lender.

How did the interest rate terms change for Eton Pharmaceuticals’ SWK loan?

The loan’s interest rate decreased from SOFR plus 6.75% to SOFR plus 6.55%. In addition, the SOFR floor, which is the minimum reference rate applied, was reduced from 5.0% to 2.75%, potentially lowering Eton’s overall borrowing cost when market rates are low.

What happened to the interest-only period in Eton Pharmaceuticals’ amended loan?

The interest-only period was extended to November 2026. Eton Pharmaceuticals can start making principal payments in May 2026 or delay those payments until November 2026, giving the company more flexibility in managing cash flow over the next several years.

Did Eton Pharmaceuticals pay any fees for the sixth amendment to its credit agreement?

Eton Pharmaceuticals did not pay any fees to SWK Funding LLC in connection with the sixth amendment. The company obtained more favorable interest terms and an extended interest-only period while keeping the maturity date unchanged, without incurring additional amendment-related costs.

When does Eton Pharmaceuticals’ amended SWK credit agreement mature?

The amended SWK credit agreement continues to mature in December 2027. While the interest rate terms and interest-only period were improved, the final maturity date of the loan remained the same, keeping the overall term length of the debt facility unchanged.

Filing Exhibits & Attachments

5 documents

Agreements & Contracts

Other Documents